About OBR - Scientific Advisory Board
OBR’s mission is to engage our academic and industry communities on-campus to foster a conversation about the health care and life sciences industry. We seek to create a global network of academic innovators from across disciplines, to connect them with each other and the industry resources necessary to move ideas forward.
Professor Graham Richards C.B.E, MA, D.Phil, D.Sc., C.Chem, FRSC
Prof Graham Richards is a former Head of Chemistry at the University of Oxford and a council member at both the Royal Society of Chemistry & the Royal Institution. He has authored 300 scientific articles & 15 books, and has been recognized with numerous awards, including the Mullard Award, Lord Lloyd of Kilgerran Prize, the Italgas Prize & the Award of the American Chemical Society for Computers in Chemical and Pharmaceutical Research. His business ventures include co-founding Oxford Molecular, and helping to establish Oxford’s technology transfer office, Isis Innovations.
Sir Gregory Winter, FRS
Sir Gregory Winter graduated from Trinity College in 1973 and will become Master of the College in October 2012. He is a genetic engineer and best known for his research and inventions relating to therapeutic antibodies. His research career was based at the Medical Research Council’s Laboratory of Molecular Biology in Cambridge, and he was until recently the Deputy Director. He has won numerous scientific awards, and also founded three biotech companies: Cambridge Antibody Technology in 1989 (bought by AstraZeneca), Domantis in 2000 (bought by GSK) and Bicycle Therapeutics in 2009.
Professor Hagan Bayley PhD, FRSC, FRS
Prof Bayley is the Professor of Chemical Biology at the University of Oxford. He enjoys working at the interface of chemistry and biology by, for example, developing techniques for protein modification that have applications in both basic science and biotechnology. Professor Bayley founded Oxford Nanopore Technology, which spun from the University of Oxford in 2005. To date, the Company has raised nearly £75 million in six rounds of private funding, from a combination of private and institutional investors.
Professor Chris Lowe
The principal focus of Professor Lowe’s biotechnology research programme over the last 30 years has been the high value – low volume sectors of pharmaceuticals, fine chemicals and diagnostics. The work not only covers aspects of biochemistry, microbiology, chemistry, electrochemistry, physics, electronics and chemical engineering, but also the entire range from pure science to strategic applied science, which has led to the establishment of 7 spin-out companies. He has 250 publications, 7 monographs and 40 patents.
Dr Marc Ventresca
Dr Marc Ventresca is an organisational and economic sociologist who teaches strategy, leadership and organisation theory at Oxford’s Saïd Business School with a focus on innovation and on how new markets get built. He also works as Senior Scholar with Center for Innovation and Communication at Stanford University. Marc holds a lead faculty role in research and teaching initiatives focused on innovation and entrepreneurship. His research investigates governance innovation among global financial markets, entrepreneurial leadership in knowledge- and information-intensive organisations, and value creation in emerging ecosystem services markets.
Simcha Jong
Simcha is an Assistant Professor (Lecturer) in Management Science and Innovation at University College London. He is a principal investigator on a number of research projects that focus on enhancing our understanding of the innovative and competitive dynamics governing new science-based industries in fields such as biotechnology. Simcha’s work has been published in international management journals such as Industrial and Corporate Change and Research Policy as well as practitioner oriented publications such as Nature Biotechnology. Simcha was elected Honorary Cambridge University European Trust Scholar and was awarded several grants and awards for his research including the first prize in the PRIME Early Career Competition and a DIME WP European Framework Grant for qualitative research on university entrepreneurship.
Tom Saylor
Tom has extensive experience in pharmaceutical development, manufacturing and marketing, and holds an MBA from Harvard University and a BSc from the Georgia Institute of Technology. His previous positions include: CEO of Sirus, a drug targeting and delivery company, based in Cambridge, England; Founder and Chairman, Lotus Healthcare Corporation, an Asian-based integrated pharmaceutical company producing and marketing analgesics, cardiovascular and gastrointestinal products; CEO of Cell Systems Limited, a medical applications company in cryopreservation and algal biotechnology.
Consulting
Innovative Business ConsultingOBR-Consulting is a unique platform to meet the growing need for consultancy at the intersection of science, business and entrepreneurship.
Learn more
Recent Comments